Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 305-314, April 2008

Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors

  • Alan A. Wilson

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5T 1R8
    • Corresponding Author InformationCorresponding author. PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8. Tel.: +1 416 979 4286; fax: +1 416 979 4656.
  • ,
  • Armando Garcia

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
  • ,
  • Jun Parkes

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
  • ,
  • Patrick McCormick

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada M5S 1A8
  • ,
  • Karin A. Stephenson

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
  • ,
  • Sylvain Houle

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5T 1R8
  • ,
  • Neil Vasdev

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8
    • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5T 1R8

Received 9 November 2007; received in revised form 13 December 2007; accepted 17 December 2007.

Abstract 

Introduction

A novel [18F]-radiolabelled phenoxyanilide, [18F]-FEPPA, has been synthesized and evaluated, in vitro and ex vivo, as a potential positron emission tomography imaging agent for the peripheral benzodiazepine receptor (PBR).

Methods

[18F]-FEPPA and two other radiotracers for imaging PBR, namely [11C]-PBR28 and [11C]-PBR28-d3, were synthesised and evaluated in vitro and ex vivo as potential PBR imaging agents.

Results

[18F]-FEPPA is efficiently prepared in one step from its tosylate precursor and [18F]-fluoride in high radiochemical yields and at high specific activity. FEPPA displayed a Ki of 0.07 nM for PBR in rat mitochondrial membrane preparations and a suitable lipophilicity for brain penetration (log P of 2.99 at pH 7.4). Upon intravenous injection into rats, [18F]-FEPPA showed moderate brain uptake [standard uptake value (SUV) of 0.6 at 5 min] and a slow washout (SUV of 0.35 after 60 min). Highest uptake of radioactivity was seen in the hypothalamus and olfactory bulb, regions previously reported to be enriched in PBR in rat brain. Analysis of plasma and brain extracts demonstrated that [18F]-FEPPA was rapidly metabolized, but no lipophilic metabolites were observed in either preparation and only 5% radioactive metabolites were present in brain tissue extracts. Blocking studies to determine the extent of specific binding of [18F]-FEPPA in rat brain were problematic due to large perturbations in circulating radiotracer and the lack of a reference region.

Conclusions

Further evaluation of the potential of [18F]-FEPPA will require the employment of rigorous kinetic models and/or appropriate animal models.

Keywords: Positron emission tomography, Peripheral benzodiazepine receptor, Rats, Microglia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(08)00007-3

doi:10.1016/j.nucmedbio.2007.12.009

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 305-314, April 2008